Success Metrics

Active Trials

4(67%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 2Efficacy & side effects

3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Detailed Status

Recruiting4

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (50.0%)

Phase 23 (50.0%)

Trials by Status

recruiting467%

not_yet_recruiting233%

Recent Activity

4 active trials

Showing 5 of 6

recruitingphase_2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

NCT07717242

not_yet_recruitingphase_1

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

NCT07692529

recruitingphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT07717242Phase 2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Recruiting

NCT07692529Phase 1

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Not Yet Recruiting

NCT07502768Phase 1

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Recruiting

NCT07555470Phase 2

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

Recruiting

NCT07372352Phase 2

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Recruiting

NCT07339527Phase 1

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6